Publications by authors named "M Alias-Ferri"
Article Synopsis
- Cannabis is the most popular illegal drug globally, with synthetic cannabinoids becoming more common, especially among individuals with opioid use disorder.
- Detection methods in clinical settings often overlook synthetic cannabinoids, which makes their usage more appealing, as individuals may wish to avoid traditional drug tests.
- A study involving 301 individuals with opioid use disorder in Spain found that 4.3% tested positive for synthetic cannabinoids, with JWH-032 and JWH-122 being the most prevalent, raising concerns about their increasing use and the lack of adequate detection methods.
Background: Cannabis is the most-frequently used illicit drug in Europe. Over the last few years in Spain, treatment demand has increased, yet most cannabis users do not seek treatment despite the related problems. A web-based self-help tool, like CANreduce 2.
View Article and Find Full Text PDF(1) Background: Since the beginning of the 21st century, the large number and wide chemical variety of new psychoactive substances (NPS) that enter the market every year has become a public health problem. Given the rapidity with which the drug market is changing, many NPS are not clinically investigated and their effects and health risks are unknown. Drug testing is a very useful tool for this purpose, but, unfortunately, it is not very widespread in individuals with opioid-use disorder under detoxification treatment.
View Article and Find Full Text PDFIntroduction: New synthetic opioids (NSO), a class of new psychoactive substances (NPS), have recently emerged and pose an upcoming global public health challenge. The effects produced by NSO are similar to those from morphine, but they present greater pharmacological potency and abuse potential. Due to the increasing number of fatal overdoses and seizures in which NSO have been detected as heroin substitutes or adulterants, individuals with Opioid Use Disorder (OUD) represent a vulnerable population.
View Article and Find Full Text PDFPurpose Of Review: Substance use disorders (SUD) affect differentially women and men. Although the prevalence has been reported higher in men, those women with addictive disorders present a more vulnerable profile and are less likely to enter treatment than men. The aim of this paper is to present an overview of how sex and gender may influence epidemiology, clinical manifestations, social impact, and the neurobiological basis of these differences of women with SUD, based on human research.
View Article and Find Full Text PDF